Ignite Creation Date:
2025-12-26 @ 11:07 AM
Ignite Modification Date:
2026-02-25 @ 9:48 PM
Study NCT ID:
NCT02332512
Status:
UNKNOWN
Last Update Posted:
2017-02-24
First Post:
2015-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)
Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01
Start Date Type:
None
Primary Completion Date:
2017-08
Primary Completion Date Type:
ESTIMATED
Completion Date:
2017-10
Completion Date Type:
ESTIMATED
First Submit Date:
2015-01-04
First Submit QC Date:
None
Study First Post Date:
2015-01-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-02-23
Last Update Post Date:
2017-02-24
Last Update Post Date Type:
ACTUAL